

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name: [Biolojic Design](https://biolojic.com/)* Website: <https://biolojic.com/>*

CEO name: [Yanay Ofra](#)* (Presenting: SVP Computational

CATEGORY: Biotech/Pharma

“AI Pharma” drug discovery, Quantum Computing.”

- **Executive Summary / Investment Rational:**
Using AI, we create superior drugs by programming antibodies to become dynamic functional switches that affect biology in new ways. Biolojic’s AI-designed antibodies provide a precise molecular effect, in the desired micro-environment, at the right time, with greater efficacy, lower toxicity, and impeccable developability. The first AI-designed antibody in the clinic was designed by Biolojic and is in phase 2.
- **Core Technology:**
Our team harnesses biology, AI and protein engineering to redefine the drug design process. Relying on big-data, our platform mimics the way the human immune system makes antibodies and creates personalized smart drugs that act like nano-robots. Unlike conventional drugs, our antibodies sense the micro-environment in a specific patient at a specific time and respond dynamically.
- **Product Profile/Pipeline:**
Our pipeline of computationally-designed therapeutics unlock the full potential of well-studied pathways. We focus on diseases that involve the delicate control mechanisms of the immune system, including cancer, autoimmune and inflammatory diseases. Our first AI-designed antibody is owned by our daughter company Aulos and is in phase 2. Two more are planned to get to the clinic early next year.
- **Business Strategy:**
We target well-understood, validated biological pathways where there is still a grave unmet need. We use our technology to design smart antibodies that affect these pathways more precisely and, therefore, can succeed where traditional drugs have failed.
- **What’s Next?**
We will continue advancing our pipeline to accelerate the discovery, preclinical, and clinical development of AI-designed antibodies while focusing on expanding AI-driven capabilities and exploring new financial opportunities, including strategic partnerships.